<DOC>
	<DOCNO>NCT00030862</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine irinotecan cisplatin treat patient locally advance unresectable metastatic cancer esophagus previously treat .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Locally Advanced Metastatic Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective tumor response rate patient previously untreated locally advanced unresectable metastatic esophageal cancer treat irinotecan cisplatin . - Determine dysphagia relief patient treat regimen . - Determine time progression overall survival patient treat regimen . - Determine safety regimen patient . OUTLINE : This multicenter study . Patients receive cisplatin IV 1-2 hour irinotecan IV 30 minute day 1 8 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 80 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma adenocarcinoma esophagus Previously untreated Locally advance unresectable metastatic disease More 50 % tumor must involve esophagus gastroesophageal ( GE ) junction tumor extend GE junction proximal stomach At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan The following consider measurable disease : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion previously irradiate area No carcinomatous meningitis untreated brain metastasis Brain metastasis allow asymptomatic patient stable taper dose steroid Large pleural effusion must previously drain sclerosed otherwise control Small , stable , asymptomatic pleural effusion allow Dysphagia allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) No know Gilbert 's disease Renal : Creatinine great 1.5 mg/dL Calcium le 12.0 mg/dL Cardiovascular : No history significant cardiovascular disease No inadequately control hypertension No unstable angina No myocardial infarction within past 6 month No ventricular cardiac arrhythmia require medication No history treatment congestive heart failure Pulmonary : No interstitial pneumonia No fibroid lung Other : No serious active infection No uncontrolled diabetes mellitus ( random blood sugar least 300 mg ) No peripheral neuropathy grade 2 great No malignancy within past 3 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , malignancy carry bad prognosis advance esophageal cancer No serious underlie medical condition would preclude study No concurrent disease would preclude study No psychiatric illness significant mental impairment would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy recover No prior radiotherapy pelvis Surgery : See Disease Characteristics Not specify Other : No concurrent phenytoin phenobarbital</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>